|Bid||1.960 x 0|
|Ask||2.000 x 0|
|Day's range||1.950 - 2.010|
|52-week range||1.190 - 2.470|
|Beta (3Y Monthly)||2.43|
|PE ratio (TTM)||N/A|
|Earnings date||13 Nov. 2018 - 19 Nov. 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.81|
Mesoblast has received US$40 million (AUD$57 million) from Tasly, comprising an upfront technology access fee of US$20 million and an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly. As consideration, Tasly has received exclusive rights and will fund all development, manufacturing and commercialization activities in China for MPC-150-IM for the treatment and prevention of chronic heart failure and MPC-25-IC for the prevention and treatment of acute myocardial infarction.
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial.
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome (HLHS) was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend. A randomized, placebo-controlled 24-patient trial is ongoing at Boston Children’s Hospital and combines an injection of MPC-150-IM into the left ventricle with corrective heart surgery in children under the age of five with HLHS.
NEW YORK and MELBOURNE, Australia, Sept. 20, 2018-- Mesoblast Limited today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease ...
Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, including the Safe Administration of Foreign Exchange, required for closing the investment agreement and the development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in China. Tasly Pharmaceutical Group (SHA:600535) is one of the largest pharmaceutical companies in China with more than 20 years of operational history.
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.8m and a trailing-twelve month of -US$41.6m, the AU$750.5m market-cap alleviates its loss by movingRead More...
MELBOURNE, Australia and NEW YORK, Aug. 29, 2018-- Mesoblast Limited today reported strong financial results and provided operational highlights for the fourth quarter and full-year ended June 30, 2018.. ...
Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has received People's Republic of China governmental approvals of Overseas Direct Investment from Tianjin Commission of Commerce and Tianjin Development and Reform Commission to enter into an investment agreement as well as a development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in China. Under the terms of the agreements with Tasly, on closing Mesoblast will receive US$40 million, comprising a US$20 million upfront technology access fee and US$20 million for equity in Mesoblast purchased by Tasly at AUD$1.86 per share.